Influence of Liraglutide, Dulaglutide Versus Conventional Treatment on Fatty liver index and Fibrosis-4 Score in Egyptian Patients with Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease.
Background and study aim: Non-alcoholic fatty liver disease (NAFLD) represents a major public health challenge in patients with type 2 diabetes mellitus (T2D). It may progress to non-alcoholic steatohepatitis( NASH), cirrhosis, and carcinoma. Our aim was to detect the changes of the fatty liver index (FLI) and FIB-4 score six months after treatment with liraglutide, or dulaglutide; novel antidiabetic medications in the Egyptian market versus the conventional therapy alone in Egyptian patients with T2D and co-existent NAFLD. Results: We found a significant improvement of the FIB-4 and FLI values in the patients who used liraglutide and dulaglutide than the conventional treatment and with better results in the liraglutide group. We noticed a significant reduction of the bodyweight, waist circumference, BMI, SBP, DBP, GGT, ALT, AST, HBA1c, triglyceride, total cholesterol, LDL-C and VLDL-C values in the liraglutide and dulaglutide groups versus the conventional treatment group. FLI, AST and Platelet count changes were the significant predictors of the change in log FIB-4 score. However, the change in log FLI was independently affected by ALT changes. Conclusion: the addition of the liraglutide or dulaglutide exhibited many clinical and metabolic beneficial effects in the patients with concomitant T2D and NAFLD.